Trastuzumab - USA

Decision on IPR: Nov 20, 2018

AIA Review	Filing Date	Institution Date	Petitioner	US Patent	Respondent	Status
IPR2017-02019	08/29/2017	03/12/2018	Pfizer, Inc.	6,339,142	Genentech, Inc.	Terminated
IPR2017-02020	08/29/2017	03/12/2018	Pfizer, Inc.	9,249,218	Genentech, Inc.	Terminated

On US’142 & US’218 patents, Pfizer previously filed IPRs (IPR2018-00330 & IPR2018-00331) on 12/18/2017 which were denied by PTAB.

US 6,339,142 (Genentech, Inc.; Exp: May 03, 2019):

1. A composition comprising a mixture of anti-HER2 antibody and one or more acidic variants thereof, wherein the amount of the acidic variant(s) is less than about 25%.

US 9,249,218 (Genentech, Inc.; Exp: May 03, 2019*TD):

1. A therapeutic composition comprising a mixture of anti-HER2 antibody and one or more acidic variants thereof, wherein the amount of the acidic variant(s) is less than about 25%, and wherein the acidic variant(s) are predominantly deamidated variants wherein one or more asparagine residues of the anti-HER2 antibody have been deamidated, and wherein the anti-HER2 antibody is humMAb4D5-8, and wherein the deamidated variants have Asn30 in CDR1 of either or both V.sub.L regions of humMAb4D5-8 converted to aspartate, and a pharmaceutically acceptable carrier.